Actin dysfunction activates ERK1/2 and delays entry into mitosis in mammalian cells.
Investigations of actin function during the cell cycle have focused primarily on cytokinesis. Here, we describe the role of actin at the entry into mitosis in primary mammalian cells. Depolymerization of actin with cytochalasin D or inhibition of myosin ATPase with butanedione-2-monoxime (BDM) at G(2) blocked the mitotic spindle formation and central positioning of the nucleus in synchronized MEF and IMR90 cells. Time-lapse microscopy confirmed that these treatments inhibit both spindle formation and separation of duplicated centrosomes to the opposite poles. Concurrent with actin dysfunction, activation of Cdc2 and nuclear localization of cyclin B1 were delayed. Furthermore, cyclin A degradation that is necessary for nuclear envelope breakdown (NEBD) in early mitosis was deferred, supporting the conclusion that mitotic onset was delayed. The activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) was sustained in these cells, and the use of a specific ERK inhibitor or a dominant negative form of ERK2 abrogated this delay of entry into mitosis. This delay of mitotic entry and the sustained ERK1/2 activity by actin dysfunction was observed only in primary cells and not in transformed cancer cell lines. These observations demonstrate that an intact actin cytoskeleton is necessary for entry into mitosis and that ERK1/2 is involved in monitoring actin dysfunction to control the onset of mitosis, suggesting the presence of an actin checkpoint at the G(2)/M transition in primary mammalian cells.
Lee
Kyunghee
K
Department of Biochemistry and Institute of Life Science and Biotechnology, College of Science, Yonsei University, Seoul, South Korea.
Song
Kiwon
K
D000199:Actins / Q000187:drug effects / Q000502:physiology*; D016203:CDC2 Protein Kinase / Q000378:metabolism; D002460:Cell Line; D016213:Cyclins / Q000378:metabolism; D015638:Cytochalasin D / Q000633:toxicity; D003931:Diacetyl / Q000031:analogs & derivatives / Q000633:toxicity; D004789:Enzyme Activation / Q000502:physiology; D006801:Humans; D015151:Immunoblotting; D018613:Microscopy, Confocal; D008856:Microscopy, Fluorescence; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D008938:Mitosis / Q000187:drug effects / Q000502:physiology*; D009218:Myosins / Q000037:antagonists & inhibitors; D008941:Spindle Apparatus / Q000187:drug effects / Q000502:physiology*
D000199:Actins; D016213:Cyclins; C004717:diacetylmonoxime; D015638:Cytochalasin D; D016203:CDC2 Protein Kinase; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D009218:Myosins; D003931:Diacetyl